Abstract
Purpose
Use of specific antihypertensive medications (AHTs) has been hypothesized to increase breast cancer risk, but results across published studies are inconsistent.
Methods
We re-evaluated the relationship between AHT use and breast cancer risk in a prospective cohort of 3,201 women ≥65 years of age at recruitment now with more than double the length of follow-up (12 vs. 5 years) and substantially more breast cancer diagnoses (188 compared with 75 cases). We estimated the association between AHT use overall as well as use of specific formulations (based on data collected annually) and breast cancer risk using multivariate-adjusted Cox regression.
Results
Compared with women who reported no use of AHTs, women who had used calcium channel blockers (CCB) within the past two years had a 1.6-fold increased risk of breast cancer (95 % confidence interval (CI): 1.0–2.5), and in particular, recent users of immediate-release CCBs had a 2.4-fold increased risk (95 % CI: 1.3–4.5). Neither ever nor recent use of any other type of AHT was associated with breast cancer risk.
Conclusions
While the observed association between immediate-release CCBs and breast cancer risk is based on a small sample size and needs to be interpreted cautiously, this result is consistent with others in the literature. However, given declines in use of these preparations in favor of sustained-release CCBs, which was not related to risk, the potential clinical and public health impact of this association is limited. This study also adds to the evidence that other commonly used AHTs are not strongly related to breast cancer risk.
Similar content being viewed by others
References
Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL (1997) Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 80(8):1438–1447. doi:10.1002/(SICI)1097-0142(19971015)80:8<1438:AID-CNCR11>3.0.CO;2-6
Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, Wallace RB, Havlik RJ (1996) Calcium-channel blockade and incidence of cancer in aged populations. Lancet 348(9026):493–497. doi:10.1016/S0140-6736(96)04277-8
Gonzalez-Perez A, Ronquist G, Garcia Rodriguez LA (2004) Breast cancer incidence and use of antihypertensive medication in women. Pharmacoepidemiol Drug Saf 13(8):581–585. doi:10.1002/pds.910
Largent JA, McEligot AJ, Ziogas A, Reid C, Hess J, Leighton N, Peel D, Anton-Culver H (2006) Hypertension, diuretics and breast cancer risk. J Hum Hypertens 20(10):727–732. doi:10.1038/sj.jhh.1002075
Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR (2003) Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years. Cancer 98(7):1504–1513. doi:10.1002/cncr.11663
Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR (1997) Calcium-channel blockers and risk of cancer. Lancet 349(9051):525–528. doi:10.1016/S0140-6736(97)80084-0
Jonas M, Goldbourt U, Boyko V, Mandelzweig L, Behar S, Reicher-Reiss H (1998) Nifedipine and cancer mortality: ten-year follow-up of 2607 patients after acute myocardial infarction. Cardiovasc Drugs Ther 12(2):177–181
Meier CR, Derby LE, Jick SS, Jick H (2000) Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 160(3):349–353
Olsen JH, Sorensen HT, Friis S, McLaughlin JK, Steffensen FH, Nielsen GL, Andersen M, Fraumeni JF Jr, Olsen J (1997) Cancer risk in users of calcium channel blockers. Hypertension 29(5):1091–1094
Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, Warshauer ME, Shapiro S (1998) Calcium channel blockers and the risk of cancer. JAMA 279(13):1000–1004
Sorensen HT, Olsen JH, Mellemkjaer L, Marie A, Steffensen FH, McLaughlin JK, Baron JA (2000) Cancer risk and mortality in users of calcium channel blockers. A cohort study Cancer 89(1):165–170. doi:10.1002/1097-0142(20000701)89:1<165:AID-CNCR21>3.0.CO;2-G
Michels KB, Rosner BA, Walker AM, Stampfer MJ, Manson JE, Colditz GA, Hennekens CH, Willett WC (1998) Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of US. women: the nurses’ health study. Cancer 83 (9):2003–2007. doi:10.1002/(SICI)1097-0142(19981101)83:9<2003:AID-CNCR17>3.0.CO;2-3
Fryzek JP, Poulsen AH, Lipworth L, Pedersen L, Norgaard M, McLaughlin JK, Friis S (2006) A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 97(3):231–236. doi:10.1007/s10549-005-9091-x
Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A et al (1991) The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1(3):263–276
Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO (1993) Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 3(4):358–366
Michels KB, Rosner BA, Manson JE, Stampfer MJ, Walker AM, Willett WC, Hennekens CH (1998) Prospective study of calcium channel blocker use, cardiovascular disease, and total mortality among hypertensive women: the Nurses’ Health Study. Circulation 97(16):1540–1548
Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW et al (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274(8):620–625
Daling JR (1996) Calcium channel blockers and cancer: is an association biologically plausible? Am J Hypertens 9(7):713–714
Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ (1996) Do calcium channel blockers increase the risk of cancer? Am J Hypertens 9(7):695–699
Mason RP (1999) Effects of calcium channel blockers on cellular apoptosis: implications for carcinogenic potential. Cancer 85(10):2093–2102. doi:10.1002/(SICI)1097-0142(19990515)85:10<2093:AID-CNCR1>3.0.CO;2-E
Correale P, Tagliaferri P, Celio L, Genua G, Montagnani S, Bianco AR (1991) Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. Eur J Cancer 27(11):1393–1395
Timcheva CV, Todorov DK (1996) Does verapamil help overcome multidrug resistance in tumor cell lines and cancer patients? J Chemother 8(4):295–299
Gupta V, Kamath N, Tkalcevic GT, Singh SV (1994) Potentiation of tamoxifen activity by verapamil in a human breast cancer cell line. Biochem Pharmacol 47(9):1701–1704
Assimes TL, Elstein E, Langleben A, Suissa S (2008) Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf. doi:10.1002/pds.1656
Acknowledgments
The Cardiovascular Health Study (http://www.chs-nhlbi.org) provided all of the subjects and specimens for this project, and Dr. Mary Lou Biggs was particularly supportive throughout. Cancer incidence data were supplied by the California Cancer Registry, North Carolina Central Cancer Registry, Pennsylvania Bureau of Health Statistics, Maryland Cancer Registry, and Johns Hopkins Training Center for Public Health Research; these institutions specifically disclaim responsibility for any analyses, interpretations, or conclusions expressed herein. This research was supported in part by a pilot grant from the Avon Foundation for women.
Conflict of interest
None to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saltzman, B.S., Weiss, N.S., Sieh, W. et al. Use of antihypertensive medications and breast cancer risk. Cancer Causes Control 24, 365–371 (2013). https://doi.org/10.1007/s10552-012-0122-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-012-0122-8